.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Managing patients who experience 15 or more headache days per month requires effective evidence-based strategies. A recent systematic review evaluates several chronic migraine prophylaxis medications to determine their clinical efficacy and patient tolerability. This extensive review synthesized data from 43 randomized controlled trials involving over 14,000 participants.
The study found that CGRP-targeted therapies, including eptinezumab, erenumab, fremanezumab, galcanezumab, and atogepant, significantly reduce monthly migraine days. Specifically, these agents reduced migraine frequency by approximately two days compared to placebo. Conversely, researchers noted that rimegepant probably has no effect on preventing chronic migraine, despite its utility in other settings.
Furthermore, the certainty of evidence for these newer therapies is generally high to moderate. While botulinum toxin slightly reduces monthly headache days, it also carries a higher risk of discontinuation due to adverse events. Consequently, clinicians must balance potential relief with the likelihood of treatment adherence. Additionally, evidence for older medications like topiramate, valproate, and propranolol remains limited for chronic cases. Most studies on these older agents carried a high risk of bias. Therefore, CGRP-targeted biologics currently offer a more reliable evidence base for patients with frequent attacks.
When selecting a therapy, physicians should consider individual patient profiles and the risk of dropout. For instance, galcanezumab may actually reduce all-cause dropout rates compared to placebo. However, traditional oral preventatives still play a role in certain clinical scenarios despite the data gaps identified in this review. Most calcitonin gene-related peptide-targeted therapies are probably effective, marking a significant advancement in chronic migraine management.
According to high-certainty evidence, CGRP-targeted therapies such as erenumab, eptinezumab, and atogepant are among the most effective for reducing monthly migraine days in adults.
While botulinum toxin provides some reduction in headache days, the review suggests it may lead to more frequent discontinuation due to side effects compared to newer CGRP-targeted options.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
New research evaluates the efficacy of CGRP-targeted therapies, botulinum toxin, and oral medications for chronic migraine prophylaxis in adults....
3 months ago
Preclinical toxicology of an equimolar D-beta-hydroxybutyrate (D-BHB) formulation for long-chain fatty acid oxidation disorders established a minipig NOAEL of 500 mg/kg BID (1000 mg/kg/day). Key acute findings included transient hypertension, tachycardia, QTc prolongation, and diarrhea at high doses.
Today
A randomized controlled trial demonstrates that combining photobiomodulation with pelvic floor muscle training significantly improves sexual function and urinary distress in women with genitourinary syndrome of menopause, offering an effective non-hormonal therapeutic option.
Today
A cross-sectional analysis from the Electronic Framingham Heart Study reveals that a higher daily heart rate per step ratio is associated with lower composite cognitive scores in older adults, highlighting smartwatch metrics as valuable tools for detecting subclinical cardiovascular factors linked to brain health.
Today
A cadaveric study compares the biomechanical strength, load-to-failure, and stiffness of tape-augmented all-soft tissue quadriceps tendon autografts against quadrupled semitendinosus constructs in ACL reconstruction, providing crucial insights for orthopaedic surgeons regarding graft selection and fixation.
Today
Metabolic dysfunction-associated fatty liver disease (MAFLD) involves severe lipid accumulation in hepatocytes. Recent research reveals that the microbial metabolite indole-3-propionic acid (IPA) activates the AHR/AMPK pathway, significantly reducing lipid synthesis and mitigating hepatic steatosis.
Today
